Find your next paid study

Children's Hospitals and Clinics of MinnesotaNCT01970696

~$10 – $750

Actual pay is set by the research site.

Lung Non-Small Cell Carcinoma

Involved-Station, Intensity-Modulated Post-Operative Radiation Therapy (I²-PORT) for Resected Non-Small Cell Lung Cancer With Residual Mediastinal Adenopathy After Neoadjuvant Therapy (ypN2)

This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or…

Alliance for Clinical Trials in OncologyNCT07293247

~$75 – $2,000

Actual pay is set by the research site.

Phase 3

Randomized Phase III Trial INcorporating Pathologic Complete ReSponse in Participants With Early StaGe Non Small Cell Lung Cancer to Optimize ImmunotHerapy in The AdjuvanT Setting (INSIGHT)

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cel…

Lung Non-Small Cell CarcinomaStage II Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8+1 more

National Cancer Institute (NCI)NCT06498635

~$50 – $1,350

Actual pay is set by the research site.

Metastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Neoplasm in the BrainOligoprogressive Lung Non-Small Cell Carcinoma+1 more

Pilot Study of 64Cu-DOTA Pembrolizumab (64CDP) in Patients Receiving Stereotactic Body Radiation Therapy (SBRT) for Oligo-Progressive Non-Small Cell Lung Cancer (NSCLC)

This phase I trial studies the safety and side effects of a new positron emission tomography (PET) imaging agent called 64Cu-DOTA-pembrolizumab to see how well…

City of Hope Medical CenterNCT07619599

~$150 – $3,000

Actual pay is set by the research site.

Advanced Anal CarcinomaAdvanced Biliary Tract CarcinomaAdvanced Bladder Carcinoma+41 more

Cancer CARE Beyond Walls - A Pilot of a Randomized, Pragmatic Trial of Cancer Directed Therapy Administration in the Patients' Homes Versus in Clinic

This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where i…

Small Cell Carcinoma of the BladderSmall Cell Carcinoma of the Urinary TractSquamous Cell Carcinoma of the Bladder+5 more

A Phase II Study of Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer

Background: Rare tumors of the genitourinary (GU) tract can appear in the kidney, bladder, ureters, and penis. Rare tumors are difficult to study because ther…

~$75 – $1,800

Actual pay is set by the research site.

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8+98 more

A Phase I/II Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)

This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patient…

Solid TumorSmall Cell Lung Cancer (SCLC)High Grade Neuroendocrine Cancer+9 more

A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Assess Safety, Tolerability, and Efficacy of EXS74539 as Monotherapy in Participants With Select Solid Tumors

The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select…

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

~$150 – $4,200

Actual pay is set by the research site.

Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8

A Randomized Phase II Study of Tepotinib With or Without Ramucirumab in Participants With MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)

This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung can…

SWOG Cancer Research NetworkNCT06031688

~$75 – $3,000

Actual pay is set by the research site.

Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more

A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerabilit…

Lung Non-Small Cell CarcinomaThoracic Cancer

~$150 – $4,500

Qualitative Study on Detection and Treatment of Thoracic Malignancies in Patients With a History of Alcohol or Substance Use Disorder

This study will attempt to identify social facilitators and barriers to detection and treatment of non-small cell lung cancer in order to learn how a history o…

University of Southern CaliforniaNCT07186699

~$10 – $750

Actual pay is set by the research site.

Lung Non-Squamous Non-Small Cell Carcinoma

Phase 2 Trial of Zipalertinib in Patients With Resectable Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion or Uncommon/Compound Mutations

This phase II trial tests how well zipalertinib with carboplatin and pemetrexed works in treating stage II-IIIB non small cell lung cancer. that can be removed…